New malaria vaccine to be tested in Africa
Print Edition
A new malaria vaccine will be tested on a large scale in Kenya, Ghana and Malawi with 360,000 children to be vaccinated between 2018 and 2020, the World Health Organization said yesterday.
The injectable vaccine RTS,S could provide limited protection against a disease that killed 429,000 people worldwide in 2015, with 92 percent of victims in Africa and two-thirds of them children under five.
“The prospect of a malaria vaccine is great news. Information gathered in the pilot will help us make decisions on the wider use of this vaccine,” said Dr Matshidiso Moeti, the WHO’s regional director for Africa.
The vaccine should be used alongside other preventative measures such as bed nets, insecticides, repellents and anti-malarial drugs.
“Combined with existing malaria interventions, such a vaccine would have the potential to save tens of thousands of lives in Africa,” Moeti said.
The vaccine, also known as Mosquirix, has been developed by the British pharmaceutical giant GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative, and the large-scale three-country pilot will test it on children aged five to 17 months.
The drug passed previous scientific testing, including a phase three clinical trial between 2009 and 2014, and was approved for the pilot program in 2015.
The aim of the trial is to assess the effectiveness of the vaccine as well as the feasibility of its delivery to populations at risk as four successive doses must be given on a strict timetable.
The immunization cycle is not in sync with routine childhood inoculations against diseases such as hepatitis, measles and meningitis, with injections required at five months, six months, seven months and two years. Symptoms of malaria include fever, muscle pain and headache as well as vomiting and diarrhoea.
While RTS,S does not promise full protection against the mosquito-borne disease it is the most effective potential vaccine so far developed, reducing the number of malaria episodes by 40 percent in tests on 15,000 people over five years of clinical trials, and could therefore save hundreds of thousands of lives.
“It’s an efficacy rate which is quite low, but given the amount of affected people, the impact will be huge,” said Mary Hamel, who is coordinating the vaccine’s implementation program. “There will be other vaccines and they’ll be more efficient, but in the meantime, this will have a significant influence.”
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
